Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors
- 14 August 2013
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 40 (10), 865-870
- https://doi.org/10.1111/cup.12202
Abstract
Epidermal growth factor receptor inhibitors (EGFRIs) are anticancer agents that have been approved for use in a variety of solid tumors. EGFR-inhibiting agents produce a variety of cutaneous adverse events: most commonly a follicular papulopustular (acneiform) eruption on the face, scalp, chest and upper back. The goal of this manuscript is to elucidate the histopathologic findings associated with this most common adverse event. The histopathological findings of 10 patients with papulopustular eruptions induced by EGFRIs are described and compared to the four prior published case series of acneiform rashes attributed to EGFRIs. All 10 patients in our case series showed a superficial, predominantly neutrophilic suppurative folliculitis with ectatic follicular infundibula and rupture of the epithelial lining. Similar pathology was found in the four other case series discussing this phenomenon. While the characteristic clinical appearance of this rash precludes the need for a biopsy in most cases, this knowledge promotes our understanding of the pathophysiologic process. As the use of EGFRIs expands, dermatopathologists will see these reactions more commonly and will need to recognize this pattern.Keywords
This publication has 13 references indexed in Scilit:
- Recommendations on management of EGFR inhibitor-induced skin toxicity: A systematic reviewCancer Treatment Reviews, 2011
- Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer PatientsClinical Cancer Research, 2010
- Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinibEuropean Journal of Cancer, 2010
- Epidermal Growth Factor Receptor Inhibitor–Related Skin Toxicity: Mechanisms, Treatment, and its Potential Role as a Predictive MarkerClinical Colorectal Cancer, 2008
- Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitorsEuropean Journal of Cancer, 2007
- Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsAnnals of Oncology, 2005
- Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachmentMolecular Cancer Therapeutics, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckJournal of Clinical Oncology, 2003